Comparative Pharmacology
Head-to-head clinical analysis: CHOLEDYL SA versus THEOPHYL 225.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEDYL SA versus THEOPHYL 225.
CHOLEDYL SA vs THEOPHYL-225
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Category C
Category C
Bronchodilator
Bronchodilator